Valuation: Grifols, S.A.

Market Cap 5.75B 6.64B 5.44B 4.92B 9.24B 637B 9.3B 64.86B 24.95B 323B 24.93B 24.37B 1,029B P/E 2026 *
12.3x
P/E 2027 * 9.41x
Enterprise Value 14.19B 16.39B 13.42B 12.15B 22.8B 1,572B 22.98B 160B 61.62B 797B 61.55B 60.18B 2,542B EV / Sales 2026 *
1.85x
EV / Sales 2027 * 1.7x
Free-Float
79.65%
Yield 2026 *
2.82%
Yield 2027 * 3.12%
1 day-0.23%
1 week-4.59%
Current month-3.30%
1 month-5.43%
3 months-3.01%
6 months-5.84%
Current year-17.52%
1 week 6.41
Extreme 6.41
6.82
1 month 6.41
Extreme 6.41
7.19
Current year 6.14
Extreme 6.14
8.23
1 year 6.14
Extreme 6.14
8.86
3 years 4.84
Extreme 4.84
10.98
5 years 4.84
Extreme 4.84
13.47
10 years 4.84
Extreme 4.84
23.65
Manager TitleAgeSince
Chief Executive Officer 58 2024-03-31
Director of Finance/CFO 49 2024-09-15
Compliance Officer 54 2013-12-31
Director TitleAgeSince
Chairman 76 2010-01-24
Director/Board Member 70 2000-04-12
Director/Board Member 62 2015-05-23
Change 5-day change 1-year change 3-year change Capi.($)
-1.68%-4.59% - - 6.64B
-2.47%-4.47%+35.19%-5.99% 77.3B
-0.22%+1.52%-13.91%-34.57% 59.52B
-1.99%+2.45%+502.05%+25.46% 57.4B
-0.56%-1.94%-11.70%+25.63% 47.91B
-0.29%+1.45%+2.14%+149.29% 46.2B
-0.55%+1.73%+50.83%-15.16% 31.94B
-0.37%-2.14%+46.43%+94.63% 24.68B
-0.26%-3.46%-1.51%+137.89% 21.08B
-1.92%-3.81%+61.03%+96.07% 15.65B
Average -0.57%-1.05%+74.51%+52.58% 42.41B
Weighted average by Cap. -0.62%-1.10%+88.92%+34.92%

Financials

2026 *2027 *
Net sales 7.65B 8.84B 7.24B 6.55B 12.3B 848B 12.39B 86.37B 33.23B 430B 33.19B 32.46B 1,371B 8.13B 9.39B 7.69B 6.96B 13.07B 901B 13.17B 91.78B 35.31B 457B 35.27B 34.49B 1,457B
Net income 536M 619M 507M 459M 861M 59.36B 868M 6.05B 2.33B 30.1B 2.32B 2.27B 95.98B 700M 808M 662M 599M 1.12B 77.5B 1.13B 7.9B 3.04B 39.3B 3.03B 2.97B 125B
Net Debt 8.45B 9.75B 7.99B 7.23B 13.57B 935B 13.67B 95.3B 36.66B 474B 36.62B 35.81B 1,512B 8.1B 9.36B 7.66B 6.94B 13.02B 897B 13.12B 91.45B 35.18B 455B 35.14B 34.36B 1,451B
Logo Grifols, S.A.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (86.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.5%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.1%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.2%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.6%), European Union (15.9%), the United States and Canada (56.5%) and other (22%).
Employees
25,258
Date Price Change Volume
26-09-15 €6.450 -1.68% 161,000
26-09-14 €6.560 -0.76% 73,653
26-09-11 €6.610 -0.75% 68,343
26-09-10 €6.660 -1.33% 43,559
26-09-09 €6.750 -0.15% 66,499
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
9.666EUR
Average target price
14.76EUR
Spread / Average Target
+52.68%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!